Neoadjuvant HER2+

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Latest News

European Commission Approves Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer
European Commission Approves Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer

January 26th 2023

Fam-trastuzumab deruxtecan-nxki has received approval in the European Union as a single agent for the treatment of patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy for metastatic disease or developed disease recurrence during or within six months of completing adjuvant chemotherapy.

Neoadjuvant Anti-HER2 TKIs Require Further Investigation for HER2+ Breast Cancer
Neoadjuvant Anti-HER2 TKIs Require Further Investigation for HER2+ Breast Cancer

January 17th 2023

Real-World Analysis Shows Low Use of Ovarian Suppression in Premenopausal HR+/HER2+ Breast Cancer
Real-World Analysis Shows Low Use of Ovarian Suppression in Premenopausal HR+/HER2+ Breast Cancer

January 9th 2023

Neoadjuvant, Adjuvant Pertuzumab/Trastuzumab Regimen Continues to Have Clinical Benefit in Early or Locally Advanced HER2+ Breast Cancer
Neoadjuvant, Adjuvant Pertuzumab/Trastuzumab Regimen Continues to Have Clinical Benefit in Early or Locally Advanced HER2+ Breast Cancer

December 30th 2022

DESTINY-Breast04 Subgroup Analysis Confirms Trastuzumab Deruxtecan Benefit in HER2-low Metastatic Breast Cancer
DESTINY-Breast04 Subgroup Analysis Confirms Trastuzumab Deruxtecan Benefit in HER2-low Metastatic Breast Cancer

December 26th 2022

Video Series
Video Interviews
Podcasts

More News